Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Nonalcoholic fatty liver disease (NAFLD) is a prevalent and increasingly diagnosed condition characterized by excessive fat accumulation in the liver. As an emerging global health concern, NAFLD has garnered considerable attention due to its close association with obesity, metabolic syndrome, type 2 diabetes, and other lifestyle-related factors. Typically asymptomatic in its early stages, NAFLD can progress to more serious conditions such as nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, or even hepatocellular carcinoma if left untreated. The exact mechanisms underlying the development of NAFLD are complex and multifactorial; however, insulin resistance plays a central role in promoting lipid deposition within hepatocytes.
1.
Video: Liver transplant for patients with advanced colorectal cancer
2.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
3.
Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.
4.
AI is useful in low-resource areas for triaging breast masses.
5.
Does pollution cause cancer?
1.
Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review
2.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
3.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
4.
Unlocking the Potential of Onivyde: A New Hope for Cancer Treatment
5.
Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
4.
Navigating the Complexities of Ph Negative ALL - Part VII
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge